The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Repros Therapeutics Inc.  (RPRX) Trade Now »     Rate RPRX  -  Discuss RPRX  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
78.5%
Top:
100.0%
Rate RPRX:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

RPRX: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Repros Therapeutics Inc. Graphic_rating_buy RPRX
Foto
62%
 -86.85%
in 153 days
<> <> <> On 5/11/09, RPRX reported that its Proellex clinical programs are progressing well and according to plan. RPRX completed enrollment of its first Pivotal Phase 3 clinical trial (ZPU-303) for the chronic treatment of uterine fibroids and expect the first Pivotal Phase 3 clinical trial for the treatment of anemia associated with uterine fibroids (ZPU-301), to be fully enrolled mid-2009, which would then lead to top-line results in each study by the end of this year. RPRX expects top-line results from its other two complementary Pivotal Phase 3 studies, ZPU-302 (anemia) and ZPU-304 (chro...
By  Marian Filo   (-24.55%  risk: aggressive)  06/10/09 Comment


BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS Graphic_rating_buy RPRX
Mikerun
73%
 -87.04%
in 154 days
<> Below are four companies with market caps under $200 million (all financial data current as of 6/9/09 during intraday trading) which have pending FDA decisions and/or clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <font> Extreme FDA and Clinical Trial Calendar Trades </font> , which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply bu...
By  Mike Havrilla   (+1.04%  risk: conservative)  06/09/09 Comment




From the Blogosphere

Repros Therapeutics: Circling the Drain to Zero

Repros Therapeutics (RPRX) is a nearly-defunct biotech company best described in ER terms as CTD (circling the drain). Despite this, it spikes periodically on rumors of I know not what. For the last few days it’s had a low of $0.88 and a high of $1.12.

<><>There are options available (unusual for a low-priced stock), meaning you can buy puts instead of shorting. (Shares are hard to borrow and the stock moves fast, so puts are definitely the safer way to play this.) The November 2.5 puts appear to be the clearest play. They have been generally purchasable in the $1.75 area or below. S...
By  trackseekingalpha   (-14.31%  risk: aggressive)  09/02/09 Comment


Mercer International Pops 50%, but Repros Therapeutics down 14%
Stop
56%
Mercer International (MERC) 52% HIGHER; since announcing it's Q2 results on July 29, share of Mercer have skyrocketed more than 340%.

ARIAD Pharmaceuticals Inc. (ARIA) 5% HIGHER; rose after the close on Friday. This morning's report was that ARIAD and its co-plaintiffs announced that the Court of Appeals granted their petition for rehearing 'En Banc' in the Lilly NF-kB patent lawsuit. Shares were up about 2% at $2.17 as many traders sold the news.

Electro-Optical Sciences, Inc. (MELA) 19% HIGHER; was a big winner after being featured in this weekend's "unusual suspects" after Barron's highli...
By  s J   (-17.38%  risk: aggressive)  08/25/09 Comment


Cash-strapped Repros Therapeutics warns of potential bankruptcy

Filed under: Earnings reports, Bad news, Employees

Repros Therapeutics (NASDAQ: RPRX) easily takes the prize for most dismal earnings report of the day. Not only did the drug firm report a wider-than-forecast second-quarter loss, it also warned that bankruptcy is a real possibility unless the company can secure significant additional capital.

<>Specifically, Repros confessed to a second-quarter net loss of $8.9 million, or 59 cents per share, compared to Wall Street's consensus estimate for a loss of 46 cents per share. The company chalked up its poor results to a 16% annualized increase in cli...
By  Elizabeth Harrow   (+23.53%  risk: conservative)  08/17/09 Comment


Red Flags at Repros Therapeutics

“What's in a name? That which we call a rose, By any other word would smell as sweet.” -- William Shakespeare in Romeo and Juliet

<>Does an old discarded penny stock traded under a flashy new name smell sweeter to investors? Apparently so. Shares of Repros Therapeutics (RPRX) have risen sharply, more than doubling since September of last year. However, I wonder if many shareholders in Repros have forgotten, or maybe never learned, that Repros is the same corporation as the discredited and oft-sued Zonagen. In 2006, after numerous failures, Zonagen changed its name to Repros and hop...
By  trackseekingalpha   (-14.31%  risk: aggressive)  01/25/09 Comment


Five Reason Repros Therapeutics Is Hitting 52-Week Highs

Five reasons Repros Therapeutics (RPRX) is hitting 52-week highs:

1. Rare among biotechs, its funding needs have been met. Last year, Repros agreed with Efficacy Capital to allow the fund to buy up to 40 percent of the outstanding shares. Despite the credit crunch, Efficacy infused $15 million to the firm and agreed to buy more should RPRX need it. The agreement is here.
By  trackseekingalpha   (-14.31%  risk: aggressive)  01/09/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +35.23% 368
2 Gerald Greene 18.14 +70.19% 206
3 stockmarketfunding.com 17.66 +25.78% 53
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +69.23% 34


POPULAR STOCKS
Symbol Company Name Sentiment
GS Goldman Sachs Group Inc The
LEH Lehman Brothers Holdings Inc
WM Washington Mutual Inc
C Citigroup Inc
SBUX Starbucks Corp
FNM Fannie Mae

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on RPRX

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Repros Therapeutics Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch